2025 · 4th Quarter (Oct 1 - Dec 31)

BRISTOL-MYERS SQUIBB COMPANY

Filed by BRISTOL-MYERS SQUIBB COMPANY.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 20, 2026
Income: Not reported
Expenses: $1,250,000.00
Registrant: BRISTOL-MYERS SQUIBB COMPANY
Client: BRISTOL-MYERS SQUIBB COMPANY
Filing UUID: 23c034d5-a8b0-4076-94cc-55f4d7c27dc6
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025

Literal federal measure citations: H.R.1492, H.R.4299

MMM · Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Literal federal measure citations: H.R.7635

TAX · Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

CPT · Copyright/Patent/Trademark

Intellectual Property Reform concerning bio-pharmaceutical industry

TRD · Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.